OndansetronAPO-Ondansetron ODT
Recommended OncologyRestrictedNot applicable line
Nausea and vomiting associated with radiotherapy or oral chemotherapy being used to treat malignancy.
1
Submissions
2020–20
On the record
—
ICER range
Not modelled
Cost basis
Decisions on record
- Meeting Dec 2022 Recommended Nausea and vomiting associated with cytotoxic chemotherapy (including methotrexate) in paediatric patients with malignancy and juvenile autoimmune conditions no PSD
- Meeting Mar 2020 Noted Nausea and vomiting associated with oral chemotherapy being used to treat malignancy
- Meeting Nov 2010 Recommended Anti-nausea drug no PSD
- Meeting Mar 2009 Recommended Antinauseant no PSD
- Meeting Jul 2008 Recommended Anti-nauseant no PSD
Access path
- TGA registered · APO-Ondansetron ODT
- Mar 2020Recommended · restricted
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
4.1 The PBAC recommended extending the existing General Schedule listings for ondansetron tablets, orally disintegrating tablets and wafers for the treatment of nausea and vomiting associated with radiotherapy, to include treatment of nausea and vomiting associated with oral chemotherapy being used to treat malignancy.PSD · Mar 2020
4.2 The PBAC noted the significant price reductions of ondansetron tablets, oral disintegrating tablets and wafers since first listing, and considered that at the current prices, the expanded use of ondansetron to include these patients would be cost- effective.PSD · Mar 2020
Cost-effectiveness
Not modelled. This is a minor submission (expansion of existing indication) with no formal economic evaluation; PBAC noted cost-effectiveness based on significant price reductions since first listing.
Cost-effectiveness accepted
Decision context
PopulationPatients receiving oral chemotherapy to treat malignancy experiencing nausea and vomiting.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2020 | Recommended · restricted | — | — | Cost-minimisation · Cost-minimisation |